Department of Medical Oncology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
Laboratory for Clinical Medicine, Capital Medical University.
Chin Med J (Engl). 2024 Aug 5;137(15):1765-1776. doi: 10.1097/CM9.0000000000003060. Epub 2024 Jun 7.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Its high recurrence rate and lack of effective control drugs result in a 5-year survival rate of only about 10%. HCC is a tumor regulated by the immune system. Significant breakthroughs have occurred in treating solid tumors with immunotherapy in recent years. Various immunotherapies, such as immune checkpoint inhibitors (ICIs), including combination therapies, have demonstrated promising therapeutic effects in both clinical applications and research. Other immunotherapies, such as adoptive cell therapies and oncolytic viruses, are also emerging, offering hope for addressing long-term survival issues in HCC. This article reviews current commonly used immunotherapy strategies and the latest research findings for reference.
肝细胞癌（HCC）是全球癌症相关死亡的主要原因。其高复发率和缺乏有效控制药物导致 5 年生存率仅约为 10%。HCC 是一种受免疫系统调控的肿瘤。近年来，免疫疗法在治疗实体瘤方面取得了重大突破。各种免疫疗法，如免疫检查点抑制剂（ICIs），包括联合疗法，在临床应用和研究中均显示出有前景的治疗效果。其他免疫疗法，如过继细胞疗法和溶瘤病毒，也正在出现，为解决 HCC 的长期生存问题带来了希望。本文综述了目前常用的免疫治疗策略和最新的研究结果，供参考。
